Back to Search
Start Over
Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the european scleroderma trials and research (eustar) cohort
- Source :
- ANNALS OF THE RHEUMATIC DISEASES, r-FISABIO. Repositorio Institucional de Producción Científica, instname, r-FISABIO: Repositorio Institucional de Producción Científica, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Annals of the Rheumatic Diseases, Volume 78, Issue 5, Annals of the Rheumatic Diseases, Vol. 78, No 5 (2019) pp. 648-656, Annals of the Rheumatic Diseases, vol. 78, no. 5, pp. 648-656
- Publication Year :
- 2019
-
Abstract
- PubMed: 30852552<br />Objectives To determine whether progressive skin fibrosis is associated with visceral organ progression and mortality during follow-up in patients with diffuse cutaneous systemic sclerosis (dcSSc). Methods We evaluated patients from the European Scleroderma Trials and Research database with dcSSc, baseline modified Rodnan skin score (mRSS) ?7, valid mRSS at 12±3 months after baseline and ?1 annual follow-up visit. Progressive skin fibrosis was defined as an increase in mRSS >5 and ?25% from baseline to 12±3 months. Outcomes were pulmonary, cardiovascular and renal progression, and all-cause death. Associations between skin progression and outcomes were evaluated by Kaplan-Meier survival analysis and multivariable Cox regression. Results Of 1021 included patients, 78 (7.6%) had progressive skin fibrosis (skin progressors). Median follow-up was 3.4 years. Survival analyses indicated that skin progressors had a significantly higher probability of FVC decline ?10% (53.6% vs 34.4%; p<br />Bayer Bayer<br />1Department of Rheumatology, University Hospital Zurich, Zurich, switzerland 2Graf Biostatistics, Winterthur, switzerland 3Clinical Development Pulmonology, Bayer Us llC, Whippany, new Jersey, Usa 4Data science and analytics, Bayer plc, Reading, UK 5Rheumatology a Department, Paris Descartes University, inseRM U1016, sorbonne, Paris Cité, Cochin Hospital, Paris, France 6Division of Rheumatology, University of Florence, Florence, italy 7Department of Medicine, Division of Rheumatology, University of Western Ontario, st. Joseph’s Health Care, london, Western Ontario, Canada 8Department of Rheumatology, Royal Free Hospital, University College london, london, UK 9scleroderma Program, Department of internal Medicine, Division of Rheumatology, University of Michigan, ann arbor, Michigan, Usa Acknowledgements The authors thank nicole schneider for excellent administration and data entry into the eUsTaR cohort. Medical writing assistance was provided by adelphi Communications ltd (Bollington, UK), funded by Bayer aG (Berlin, Germany).<br />This study was supported by a grant from Bayer aG.
- Subjects :
- INVOLVEMENT
Male
BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences
diffuse
Time Factors
Databases, Factual
Skin Diseases/etiology/mortality/physiopathology
PREDICTION
Fibrosi
2745 Rheumatology
Diffuse/complications/mortality/pathology
Immunology
General Biochemistry, Genetics and Molecular Biology
Immunology and Allergy
Rheumatology
Kaplan-Meier Estimate
ddc:616.07
Severity of Illness Index
Scleroderma
Cohort Studies
PROGNOSTIC-FACTORS
Fibrosis
Medicine and Health Sciences
scleroderma
Lung
Skin
integumentary system
progressive skin fibrosis
Lung function decline
BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti
10051 Rheumatology Clinic and Institute of Physical Medicine
DEATH
Middle Aged
ddc
Europe
VARIABILITY
factual
Cohort
Visceral organ progression
2723 Immunology and Allergy
Disease Progression
Female
Survival Analysi
Life Sciences & Biomedicine
Cohort study
Human
Adult
Skin/pathology
medicine.medical_specialty
databases
All-cause death
risk analysis
diffuse cutaneous systemic sclerosis
610 Medicine & health
IMPROVEMENT
Systemic Sclerosis
Skin Diseases
THICKNESS SCORE
VALIDATION
Databases
FEV1/FVC ratio
1300 General Biochemistry, Genetics and Molecular Biology
Internal medicine
medicine
Humans
Factual
Survival analysis
2403 Immunology
Science & Technology
Proportional hazards model
business.industry
Surrogate endpoint
MORTALITY
Skin Disease
fibrosis
Progressive skin fibrosi
Lung/physiopathology
biomarkers
Diffuse cutaneous systemic sclerosi
medicine.disease
Survival Analysis
all-cause death
lung function decline
visceral organ progression
adult
cohort studies
databases, factual
disease progression
female
humans
Scleroderma, Diffuse
Cohort Studie
business
Subjects
Details
- Language :
- English
- ISSN :
- 30852552, 00034967, and 14682060
- Database :
- OpenAIRE
- Journal :
- ANNALS OF THE RHEUMATIC DISEASES, r-FISABIO. Repositorio Institucional de Producción Científica, instname, r-FISABIO: Repositorio Institucional de Producción Científica, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Annals of the Rheumatic Diseases, Volume 78, Issue 5, Annals of the Rheumatic Diseases, Vol. 78, No 5 (2019) pp. 648-656, Annals of the Rheumatic Diseases, vol. 78, no. 5, pp. 648-656
- Accession number :
- edsair.doi.dedup.....4a10afd1863ddb71842a5c0fab30521a